Developing infrared imaging tools to digitally stain tissue for pathology
Pathologists diagnose disease by examining tissue sections after preparation and chemical staining. Rising test demand and shortages of pathologists and laboratory staff put pressure on diagnostic services. Sample staining and image interpretation remain workflow bottlenecks.
ADMIR develops imaging instruments and software for tissue analysis. Its approach combines infrared and visible-light images with deep learning to digitally stain tissue, aiming to replace chemical staining in pathology laboratories.
What stands out about ADMIR
A peer-reviewed prostate-tissue study reports initial evidence for ADMIR digital staining in image assessment and Gleason grading.
ADMIR and CRCL participate in TUMADMIR, an ANR-backed cancer-imaging project awarded over €360,000 and starting in 2025.
ADMIR holds an exclusive licence to CEA patents arising from its technology development.
A 2023 pre-seed financing supported equipment purchases and team expansion.
ANR identifies ADMIR as a CEA-Leti spin-off created in 2022 to develop infrared multispectral imaging.
ADMIR's infrared multispectral imaging technology won the i-Lab innovation competition in 2022, according to ANR.
Co-founder Laurent Duraffourg previously directed CEA-Leti's optics and photonics laboratory and worked there as a researcher.
Co-founder Philippe Andreucci previously co-founded APIX Technology, as documented by Bpifrance.
ADMIR’s water-microbiology prototype study used 3,230 colonies from 11 strains and reported 96.5% mean correct identification.
CORDIS lists ADMIR with a €122,911.69 net EU contribution in ATHENA, an infrared-imaging consortium running from 2024 to 2027.
Co-founder Mathieu Dupoy has led CEA multispectral infrared imaging projects for biological applications since 2015.
Get a curated pipeline of healthcare and life sciences startups aligned with your investment thesis.